Tommaso Martino De Pas
Overview
Explore the profile of Tommaso Martino De Pas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
201
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Guglielmo P, Mazzola R, Darwish S, Valenti F, De Pas T, Setti L, et al.
Eur J Nucl Med Mol Imaging
. 2025 Mar;
PMID: 40067459
Purpose: This review systematically compared, in a head-to-head manner, the diagnostic and prognostic performance of [F]FDG and [F]FES PET/CT in breast cancer (BC) patients. Methods: A systematic literature search was...
2.
De Pas T, Giaccone G, Catania C, Conforti F, Pala L, Mitsakis P, et al.
Curr Oncol
. 2025 Feb;
32(2).
PMID: 39996868
The antitumor activity of immunotherapy is strongly influenced by the presence of driver gene mutations/translocations. For this reason, knowledge of the predictive value of specific genetic alterations in relation to...
3.
Valenza C, Trapani D, Porta F, Olmeda E, Gaeta A, Boscolo Bielo L, et al.
Oncologist
. 2025 Feb;
30(2).
PMID: 39921370
Background: In patients with phyllodes tumors of the breast, the presence of mediator of RNA polymerase II transcription subunit 12 homolog mutations (MED12m) and a history of previous fibroadenoma may...
4.
Valenza C, De Pas T, Gaeta A, Castellano G, Santoro C, Corona A, et al.
Eur J Cancer
. 2023 Nov;
196:113423.
PMID: 37977104
Background: The treatment for primary malignant phyllodes tumors of the breast (B-MPT) consists of wide local excision with negative margins (≥1 cm). However, because of their rarity, prognostic factors, type...
5.
DAmbrosio L, Fumagalli E, De Pas T, Nannini M, Bertuzzi A, Carpano S, et al.
JAMA Netw Open
. 2023 Nov;
6(11):e2341522.
PMID: 37930700
Importance: Gastrointestinal stromal tumor (GIST) follow-up is recommended by international guidelines, but data on the role of follow-up in patients with low relapse risk are missing. For these patients, the...
6.
Zagami P, Comandone A, Fiore M, Baldi G, Grignani G, Vincenzi B, et al.
Cancer Med
. 2023 Jul;
12(16):17047-17055.
PMID: 37455549
Background: After a huge efficacy of imatinib in treating patients with gastrointestinal stromal tumors (GISTs) was proven, a maximum effort was made to make a differential diagnosis between GISTs and...
7.
Iacomino N, Scandiffio L, Conforti F, Salvi E, Tarasco M, Bortone F, et al.
Biomedicines
. 2023 Mar;
11(3).
PMID: 36979710
The thymus is widely recognized as an immunological niche where autoimmunity against the acetylcholine receptor (AChR) develops in myasthenia gravis (MG) patients, who mostly present thymic hyperplasia and thymoma. Thymoma-associated...
8.
Conforti F, Pala L, Vivanet G, Corti C, Catania C, Maiettini D, et al.
Lung Cancer
. 2023 Jan;
176:98-102.
PMID: 36630822
Background: We reported the efficacy and safety results of high-dose, continuous-infusion Ifosfamide,in patients with advanced thymoma (TM) and thymic carcinoma (TC). Methods: This was a multicentric, prospective study in patients...
9.
Conforti F, Zucali P, Pala L, Catania C, Bagnardi V, Sala I, et al.
Lancet Oncol
. 2022 Sep;
23(10):1287-1296.
PMID: 36096156
Background: Patients with advanced type B3 thymoma and thymic carcinoma resistant to chemotherapy have few treatment options. We report the efficacy and safety results of the combination of the anti-PD-L1...
10.
Conforti F, Tarantino P, Trillo P, Pala L, Zagami P, Pirola S, et al.
Cancer Treat Rev
. 2020 Dec;
92:102133.
PMID: 33296826
Background: Primary enteric adenocarcinoma of the thymus (EAT) is a recently proposed rare subtype of thymic carcinoma. Unlike thymic carcinomas with squamous histology, for which clinical guidelines are available, little...